FLGT Stock Analysis: Fulgent Genetics | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 592m USD | 12M Return: 5.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.37M
Qual. Beats: 0
Rev. Trend: 60.7%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 9.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Fulgent Genetics, Inc. (NASDAQ: FLGT) is a U.S.-based clinical diagnostics and therapeutic development company headquartered in El Monte, California, founded in 2011 and renamed from Fulgent Diagnostics in August 2016. It provides a broad range of diagnostic services to physicians and patients domestically and internationally, including molecular and genetic testing, anatomic pathology across multiple subspecialties (gastrointestinal, dermatopathology, urologic, breast, neuropathology, and hematopathology), oncology testing, and sequencer-based services for hereditary cancer, reproductive health, and other conditions.
In parallel with its diagnostic business, Fulgent is developing cancer drug candidates using a proprietary nanoencapsulation and targeted therapy platform intended to improve the therapeutic window and pharmacokinetic profile of oncology treatments. The company also operates a consumer-facing Picture Genetics platform, which combines gene probes, suppression and comparison algorithms, adaptive learning software, and a proprietary laboratory information management system (LIMS) to help customers interpret personal DNA data. Its customer base spans hospitals, medical institutions, reference laboratories, insurance payors, governmental bodies, large corporations, and individual patients.
Fulgent operates in the Health Care Services sub-industry, which encompasses companies that deliver clinical and diagnostic services to providers, payors, and patients. The clinical diagnostics segment benefits from longer-term tailwinds including an aging population, rising demand for personalized and genomic medicine, and increased adoption of genetic testing in oncology and reproductive health.
- Core testing growth offsets COVID revenue decline
- Nanoencapsulation cancer drug pipeline advances in clinical trials
- Strong cash balance funds share buybacks and bolt-on acquisitions
| Net Income: -73.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA -7.16 > 1.0 |
| NWC/Revenue: 121.4% < 20% (prev 120.0%; Δ 1.43% < -1%) |
| CFO/TA -0.08 > 3% & CFO -90.1m > Net Income -73.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.9m) vs 12m ago 0.16% < -2% |
| Gross Margin: 38.71% > 18% (prev 38.80%; Δ -0.08% > 0.5%) |
| Asset Turnover: 27.12% > 50% (prev 24.25%; Δ 2.87% > 0%) |
| Interest Coverage Ratio: -422.0 > 6 (EBIT TTM -82.7m / Interest Expense TTM 196k) |
| A: 0.34 (Total Current Assets 479.0m - Total Current Liabilities 90.1m) / Total Assets 1.16b |
| B: 0.44 (Retained Earnings 505.1m / Total Assets 1.16b) |
| C: -0.07 (EBIT TTM -82.7m / Avg Total Assets 1.18b) |
| D: 9.36 (Book Value of Equity 1.05b / Total Liabilities 112.2m) |
| Altman-Z'' = 12.98 = AAA |
| DSRI: 0.86 (Receivables 75.7m/80.4m, Revenue 320.3m/292.4m) |
| GMI: 1.00 (GM 38.80% / 38.71%) |
| AQI: 0.85 (AQ_t 0.48 / AQ_t-1 0.57) |
| SGI: 1.10 (Revenue 320.3m / 292.4m) |
| TATA: 0.01 (NI -73.8m - CFO -90.1m) / TA 1.16b) |
| Beneish M = -3.16 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 20.55 with a total of 207,256 shares traded. Over the past week, the price has changed by -1.44%, over one month by +8.56%, over three months by +42.41% and over the past year by +5.12%.
Current recommended Stop Loss: 19.70 (which is 4.1% or 1.2 ATR below the current price).
Fulgent Genetics has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold FLGT.
- StrongBuy: 0
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.5 | -10% |
P/E Forward = 7.7042
P/S = 1.8485
P/B = 0.5643
P/EG = 1.32
Revenue TTM = 320.3m USD
EBIT TTM = -82.7m USD
EBITDA TTM = -58.5m USD
Long Term Debt = 1.48m USD (from longTermDebt, last quarter)
Short Term Debt = 2.69m USD (from shortTermDebt, last quarter)
Debt = 18.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.94m
Net Debt = -258.2m USD (calculated: Debt 18.1m - CCE 276.3m)
Enterprise Value = 334.0m USD (592.2m + Debt 18.1m - CCE 276.3m)
Interest Coverage Ratio = -422.0 (Ebit TTM -82.7m / Interest Expense TTM 196k)
EV/FCF = -2.95x (Enterprise Value 334.0m / FCF TTM -113.2m)
FCF Yield = -33.89% (FCF TTM -113.2m / Enterprise Value 334.0m)
FCF Margin = -35.33% (FCF TTM -113.2m / Revenue TTM 320.3m)
Net Margin = -23.04% (Net Income TTM -73.8m / Revenue TTM 320.3m)
Gross Margin = 38.71% ((Revenue TTM 320.3m - Cost of Revenue TTM 196.3m) / Revenue TTM)
Gross Margin QoQ = 30.21% (prev 39.10%)
Tobins Q-Ratio = 0.29 (Enterprise Value 334.0m / Total Assets 1.16b)
Interest Expense / Debt = 1.08% (Interest Expense 196k / Debt 18.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -65.3m (EBIT -82.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.31 (Total Current Assets 479.0m / Total Current Liabilities 90.1m)
Debt / Equity = 0.02 (Debt 18.1m / totalStockholderEquity, last quarter 1.05b)
Debt / EBITDA = 4.41 (negative EBITDA) (Net Debt -258.2m / EBITDA -58.5m)
Debt / FCF = 2.28 (negative FCF - burning cash) (Net Debt -258.2m / FCF TTM -113.2m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.25% (Net Income -73.8m / Total Assets 1.16b)
RoE = -6.70% (Net Income TTM -73.8m / Total Stockholder Equity 1.10b)
RoCE = -7.50% (EBIT -82.7m / Capital Employed (Equity 1.10b + L.T.Debt 1.48m))
RoIC = -6.21% (negative operating profit) (NOPAT -65.3m / Invested Capital 1.05b)
WACC = 6.94% (E(592.2m)/V(610.3m) * Re(7.13%) + D(18.1m)/V(610.3m) * Rd(1.08%) * (1-Tc(0.21)))
Discount Rate = 7.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.41 | Cagr: 1.64%
[DCF] Fair Price = unknown (Cash Flow -113.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.10 | # QB: 0
Revenue Correlation: 60.74 | Revenue CAGR: 3.47% | SUE: 1.31 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.44 | Chg30d=-38.25% | Revisions=-25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.37 | Chg30d=-45.45% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=-1.57 | Chg30d=-11.48% | Revisions=-25% | GrowthEPS=-473.4% | GrowthRev=+8.8%
EPS next Year (2027-12-31): EPS=-1.53 | Chg30d=-2.89% | Revisions=-25% | GrowthEPS=+2.6% | GrowthRev=+14.6%
[Analyst] Revisions Ratio: -50% (up=0, down=3)